EFFECTS OF MONTELUKAST AND PREDNISOLONE ON KIDNEY ANTI-OXIDANT LEVELS

ABSTRACT

Chronic asthma is a respiratory condition marked by oxidative stress and inflammation of the airways. Prednisolone and montelukast are two drugs that are often used to treat asthma. Their impact on endogenous antioxidant levels in asthmatic situations is yet unknown, however.Medication for asthma might include bronchodilators, corticosteroids (like Prednisolone), and leukotrine receptor antagonists (like Montelukast). Free radicals may be neutralized by antioxidants, which also lessen oxidative stress in the body.As a selective antagonist of the leukotriene D4 (LTD4) receptor, montelukast acts by preventing the body's production of leukotrienes, which are substances that promote inflammation and constriction of the airways when they come into contact with allergens.One corticosteroid that is often used to treat asthma is prednisolone. The purpose of this work was to examine the effects of prednisolone and montelukast on endogenous antioxidant levels in Sprague Dawley rats with asthma. Two primary groups of Sprague Dawley rats were created (control and test groups). Group 1 control is not induced with asthma, while Group 2 negative control is induced with asthma but not treated. These two groups make up the control group. While Group 3 (asthma induced and treated with montelukast) and Group 4 (asthma induced and treated with prednisolone) comprise the test group, five rats in every group. The rats were sensitized to ovalbumin (100 ug) on day 14, and then they were challenged with ovalbumin 0.5% w/v (dissolved in 100 mg/ml aluminum hydroxide and saline) three times a week for four weeks, using a Medal family nebulizer. This caused the rats to develop asthma. The tested groups received 10 mg/kg of montelukast and 5 mg/kg of prednisolone throughout the challenge period.Rat blood samples were taken at the conclusion of the treatment period. Measurements were made of the amounts of endogenous antioxidants, such as total protein and total antioxidant levels, glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD).The findings demonstrated that there was no statistically significant variation in the levels of antioxidants in any of the test groups for either glutathione peroxidase or catalase.Super-Oxide Dismutase was considerably increased after Montelukast treatment.All test groups had considerably lower glutathione levels than the control group.All test groups' total protein levels were much lower than those of the control group. Significantly lower total antioxidant levels were seen in the negative control test group.As a result, the research concludes that while prednisolone lowers antioxidant levels as evidenced by total protein and glutathione levels, montelukast can increase antioxidant levels as seen in super oxide dismutase, reducing oxidative stress in kidney tissues. This is because corticosteroids can inhibit the synthesis of endogenous antioxidants, which increases oxidative stress and damages renal tissues while also promoting inflammation.